Related Experiment Video
Updated: May 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Boceprevir and treatment of chronic hepatitis C
1Gastroenterology/Hepatology Division, Indiana University School of Medicine, Indianapolis, 46202-5121, USA. pkwo@iupui.edu
Abstract:
The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment naïve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Ulcerative Colitis in IBD
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

